MANDI MEARS: Open Payments
NPI 1710220959 · CONWAY, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$894 in 48 payments from 10 companies in 2025. Trend: 2023 $574 · 2024 $984 · 2025 $894
Food & beverage: $894
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 17 | $312 |
| ABBVIE INC. | 12 | $135 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $96 |
| PFIZER INC. | 3 | $63 |
| Phathom Pharmaceuticals, Inc. | 4 | $42 |
| Exact Sciences Corporation | 2 | $37 |
| Lilly USA, LLC | 2 | $34 |
| Astellas Pharma US Inc | 1 | $34 |
| Abbott Laboratories | 1 | $19 |
Products named: JOURNAVX, BREZTRI, CAPLYTA, FARXIGA, AIRSUPRA, VRAYLAR, VOQUEZNA, QULIPTA.
Industry payments across AR — which companies pay providers there.
